A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

Trial Details

NCT ID
NCT06115135
Phase
PHASE2
Sponsor
Oncotherapeutics
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Venetoclax
Locations (sample)
  • West Hollywood, California, United States|34.09001,-118.36174
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Subjects must meet all the following inclusion criteria to be eligible to enroll in this study.
  • Has a diagnosis of MM based on standard criteria as follows: Myeloma Criteria: Must be At least 1 of 2
  • Clonal bone marrow plasma cells \>10%
  • Biopsy-proven bony or extramedullary plasmacytoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →